Lamivudine Teva Pharma B.V (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics natural nucleosides. When viral reverse transcriptase or hepatitis B DNA polymerase incorporates it into viral DNA, the chain is terminated, preventing further replication of the virus.

The specific dose of lamivudine is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function and other clinical factors. Patients should follow the exact regimen provided by their prescriber.

Safety data for lamivudine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with some older NRTIs, lamivudine has a more favorable safety profile and a lower incidence of mitochondrial toxicity, though resistance can develop if adherence is poor.

Lamivudine tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability throughout its shelf life.

Lamivudine is taken orally, usually as a tablet, with or without food. The exact timing and frequency are prescribed by the treating physician, who will consider the patient’s overall treatment regimen.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity and pancreatitis. Patients should be monitored for signs such as unexplained abdominal pain, rapid breathing, jaundice or severe fatigue, and seek medical attention promptly if these occur.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in combination with medications that have major interaction risks unless closely monitored.